In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.
CITATION STYLE
Maziarz, R. T. (2010, March 11). Transplantation for CML: 2010. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2009-12-255844
Mendeley helps you to discover research relevant for your work.